Clinical Trials Bulletin
New Approaches for Pancreatic Cancer: Two Trials for Pancreatic Cancer from the STAND UP 2 CANCER Initiative
√ Research Study for Newly Diagnosed, Advanced or Metastatic Pancreatic Cancer
A phase I/II pharmacodynamic study of hydroxychloroquine (HCQ) in combination with gemcitabine/abraxane to inhibit autophagy in pancreatic cancer.
√ Research Study for Previously Untreated Metastatic Pancreatic Cancer
Phase II Study of Gemcitabine and nab-Paclitaxel in Combination with Vismodegib (GDC-0449;Hedgehog Inhibitor) in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas.
Research Studies for Colon and Rectal Cancer
√ Research Study for Advanced or Metastatic Colon or Rectal Cancer
A phase I/II/pharmacodynamic study of hydroxychloroquine in combination with FOLFOX plus bevacizumab to inhibit autophagy in colorectal cancer.
√ Research Study for Advanced or Metastatic Rectal Cancer
DCE-MRI PET Bevacizumab Study in Rectal Cancer: A phase II/pharmacodynamic study of preoperative or definitive FOLFOX plus bevacizumab, with the additional pharmacodynamic goal of assessing tumor blood flow as measured by dynamic contrast enhanced MRI, and the induction of hypoxia and apoptosis as measured by PET in patients with rectal cancer.